In the interviews they mention a synergystic effect of taking two antiretrovirals. I couldn't find numbers in the study about that. How did you figure your dose?
"Our study showed that these drugs inhibited XMRV at lower concentrations when two of them were used together, suggesting that possible highly potent 'cocktail' therapies might inhibit the virus from replicating and spreading," said Schinazi. "This combination of therapies might also have the added benefit of delaying or even preventing the virus from mutating into forms that are drug-resistant." Singh and Schinazi are currently investigating the development of viral resistance to raltegravir and other active drugs.
from plosone
Comparison of RT inhibitors zidovudine (AZT), lamivudine (3TC), didanosine (ddI), stavudine (d4T), abacavir (ABC), tenofovir (TDF), and phosphonic acid derivative foscarnet, showed only AZT and TDF to be effective at blocking XMRV replication at similar concentrations to those that inhibited HIV-1. As shown in Figure 5, the susceptibility of XMRV to AZT (0.045 0.007 M) was similar to HIV-1 (0.03 0.014 M). In the case of 3TC, XMRV was about 10-fold more resistant to 3TC (36.9 5.2 M) in comparison to HIV-1(3.4 1.4 M). This was also true for ddI (110 62.4 M), d4T (9.0 4.2 M), and ABC (14.4 0.45 M). The IC50 of TDF for XMRV was 3.9-fold higher than that of HIV-1 (1.48 1.05 M versus 0.38 0.13 M, respectively) and foscarnet failed to inhibit XMRV infection even at a concentration of 250 M. HIV-1 integrase inhibitor, raltegravir, was
able to inhibit XMRV at nanomolar concentrations (0.82 0.07 nM), with XMRV being 2.5-fold more susceptible in comparison to HIV-1 (2.25 0.21 nM). Overall, these results suggest that AZT, TDF, and raltegravir can effectively inhibit XMRV infection at concentrations that are similar to those needed to inhibit HIV-1 infection, whereas substantially higher doses of 3TC, ddI, d4T, and ABC are required to inhibit XMRV infection.